A Prospective, Single Center, Single-Arm Clinical Study of 20 Participants to Reduce the Appearance of the Peri-orbital Wrinkles. Participants Will Receive up to Four Treatments With Tixel Every 4 Weeks. Follow-up Will Occur 1 Month and 3 Months Following Last Treatment.

Wrinkle Clinical Trial

Official title:

A Prospective, Single-arm Clinical Study Evaluating the Safety and Effectiveness of the Tixel Fractional System in the Treatment of Periorbital Wrinkles

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05282979
• Other study ID #: PLDI101
• Status: Recruiting
• Phase: N/A
• Start date: August 20, 2021
• Est. completion date: August 20, 2022

Study information

• Verified date: March 2022
• Source: Physicians Laser and Dermatology Institute
• Contact: Megan Calderon
• Phone: 3122800890
• Email: megan[@]pldilaser.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Prospective, Single center, Single-Arm Clinical Study of 13-20 study participants who are seeking a procedure to reduce the appearance of the peri-orbital wrinkles. Each study participant will receive up to four (4) treatments with the Tixel in a monthly interval. Follow-up will occur 1 month and 3 months following last treatment.

Description:

A Prospective, Single center, Single-Arm Clinical Study of 13-20 participants who are seeking a procedure to reduce the appearance of the peri-orbital wrinkles, and meet study eligibility criteria, and have provided informed consent will be enrolled in the study. Each study participate will receive up to 4 treatments with Tixel in monthly interval. Follow-up will occur at 1 month and 3 months following the last visit.

The clinic visits will be as follow:

1. Base line (1st tx)

2. Phone-call visit (3 days after the first treatment)

3. 4 week (2nd tx)

4. 8 week (3rd tx)

5. 12 week (4th tx)

6. 4 weeks after the last treatment (1st Follow-up)

7. 12 weeks after the last treatment (2nd follow-up = 3 months follow-up, primary endpoint and the study completion visit)

Primary Safety Endpoint is the evaluation of related adverse events up to the 3-month visit after treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: August 20, 2022
• Est. primary completion date: August 20, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female 35-75 years old diagnosed with clinically evident fine (mild) to moderate depth periorbital wrinkles.

2. Willingness and ability to comply with all required study activities including returning for follow-up visits and protocol requirements.

3. The subject is able to provide written informed consent and perform the study's activities according to HIPAA guidelines.

4. Fitzpatrick wrinkle score of 3-7 in the peri-orbital areas per the treating investigator.

5. Stable body weight during the study period.

6. Skin Type I - V as per Fitzpatrick Skin Scale

Exclusion Criteria:

1. Past treatment with Tixel device.

2. The subject may not undergo treatment by the Tixel device according to the device's contra-indications for use, as defined in the User Manual and in the Instructions for Use and by any other labeling of the device.

3. Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.

4. Female subjects who are pregnant, or planning to become pregnant, or have given birth less than 3 months ago or are lactating.

5. Subjects with significant exposure to critical amounts of ultraviolet light (Suntan).

6. Subjects who have had the following treatments:

1. a cosmetic procedure to improve periorbital rhytides within 6 months.

2. Injectable filler in temples and in the upper face area to be treated within 12 months of investigation.

7. Any subject who have visible scars or other visible changes over the treated areas that may affect evaluation of response and/or quality of photography.

8. Subjects with any type of active cut, wound, inflammation, lesion (benign, premalignant or malignant) or active bacterial, viral, fungal, or herpetic infection on the skin on the designated treatment sites or in close proximity to it.

9. Existing or history of the following (when discussing skin conditions, refers only to the periorbital sites):

1. skin malignancy, or any diagnosis of suspected malignancy

2. Collagen or vascular or bleeding disease

3. Immunosuppression or autoimmune disease

4. History of persistent beyond 2 years post inflammatory hyperpigmentation.

5. Active Acne Vulgaris, HSV-1, or any existing skin condition/disease that in the investigator's opinion would interfere with the evaluation of the safety of the study treatment and evaluation.

6. Any skin condition which can induce bullous lesions, urticaria, or demonstrate a Koebner phenomenon (psoriasis, lichen planus, etc.).

7. Any disease that inhibits pain sensation

8. History of keloid formation.

9. Conditions affecting healing rate (i.e. diabetes mellitus I or II, vascular condition, etc.)

10. neuromuscular disorders

10. Subjects who have used, within 30 days, any medication over the periorbital area that can cause dermal hypersensitivity or affect skin characteristics over the treated area (i.e. topically applied retinoids, hydroquinone, Chemical peel of any strength: glycolic acid, lactic acid, salicylic acid)

11. Subjects who have used, systemic treatment which may induce dyspigmentation within 12 months, such as amiodarone, clofazinmine, minocycline or chloroquine.

12. Subjects currently taking or have taken an oral retinoid in the past 6 months;Subjects currently taking long-term oral steroid treatment.

13. Concurrent therapy that, in the principal investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study treatment.

14. Subjects who anticipate the need for major surgery or overnight hospitalization during the study that can affect the study schedule or treatment evaluation.

15. Enrollment in any active study involving the use of investigational devices or drugs which would impact the periorbital response.

16. Any other cause per the principal investigator's discretion.

Related Conditions & MeSH terms

• Wrinkle

Intervention

Device:
• Tixel 2
Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.

Locations

Country	Name	City	State
United States	Physicians Laser & Dermatology Institute, LLC	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Physicians Laser and Dermatology Institute

Country where clinical trial is conducted

United States, 

References & Publications (10)

Fitzpatrick RE, Goldman MP, Satur NM, Tope WD. Pulsed carbon dioxide laser resurfacing of photo-aged facial skin. Arch Dermatol. 1996 Apr;132(4):395-402. — View Citation

Ganceviciene R, Liakou AI, Theodoridis A, Makrantonaki E, Zouboulis CC. Skin anti-aging strategies. Dermatoendocrinol. 2012 Jul 1;4(3):308-19. doi: 10.4161/derm.22804. — View Citation

Gold AH, Pozner J, Weiss R. A Fractional Bipolar Radiofrequency Device Combined with a Bipolar Radiofrequency and Infrared Light Treatment for Improvement in Facial Wrinkles and Overall Skin Tone and Texture. Aesthet Surg J. 2016 Oct;36(9):1058-67. doi: 10.1093/asj/sjw086. Epub 2016 Jul 29. — View Citation

Gupta MA, Gupta AK. Photodamaged skin and quality of life; reasons for therapy. J Dermatol Treat 1996; 7:261-264

Hruza G, Taub AF, Collier SL, Mulholland SR. Skin rejuvenation and wrinkle reduction using a fractional radiofrequency system. J Drugs Dermatol. 2009 Mar;8(3):259-65. — View Citation

Kim JK, Roh MR, Park GH, Kim YJ, Jeon IK, Chang SE. Fractionated microneedle radiofrequency for the treatment of periorbital wrinkles. J Dermatol. 2013 Mar;40(3):172-6. doi: 10.1111/1346-8138.12046. Epub 2012 Dec 17. — View Citation

Manríquez JJ, Majerson Gringberg D, Nicklas Diaz C. Wrinkles. BMJ Clin Evid. 2008 Dec 16;2008. pii: 1711. Review. — View Citation

Michaud T, Gassia V, Belhaouari L. Facial dynamics and emotional expressions in facial aging treatments. J Cosmet Dermatol. 2015 Mar;14(1):9-21. doi: 10.1111/jocd.12128. Epub 2015 Jan 24. — View Citation

Mulholland RS, Ahn DH, Kreindel M, Paul M. Fractional Ablative Radio-Frequency Resurfacing in Asian and Caucasian Skin: A Novel Method for Deep Radiofrequency Fractional Skin Rejuvenation. Journal of Cosmetics, Dermatological Sciences and Applications. 2012;2(3):144-150

Park SE, Kim SS, Kim CW, Her Y. A Prospective Split-Face Comparative Study of Periorbital Wrinkle Treatments: Fractional Erbium-Doped Yttrium Aluminum Garnet Laser, Intense Pulsed Light, and Topical 0.1% Tretinoin Cream. Ann Dermatol. 2016 Oct;28(5):650-652. Epub 2016 Sep 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Adverse Events report	Evaluation of related adverse events up to the 3-month after last treatment visit	Up to 12 months
Primary	Effectiveness using Fitzpatrick Wrinkle Classification Scale (FWCS)	Comparison of the proportion of subjects with a = 1-score improvement on the Fitzpatrick Wrinkle Classification Scale (FWCS) at the 3-month visit compared to baseline. The FWCS is a clinically validated assessment tool used to assess skin wrinkle severity and elastosis on a scale from 1 through 9, where the lower score is considered better.	Up to 12 months
Secondary	Effectiveness using Fitzpatrick Wrinkle Classification Scale (FWCS)- Unblinded	Assessment of improvement using Fitzpatrick Wrinkle Classification Scale (FWCS) at each visit compared to baseline by the handling physician. The FWCS is a clinically validated assessment tool used to assess skin wrinkle severity and elastosis on a scale from 1 through 9, where the lower score is considered better.	Up to 12 months
Secondary	Effectiveness using GAIS-Global Aesthetic Improvement Scale Assessment-Unblinded	Assessment of improvement using Global Aesthetic Improvement Scale Assessment at 1 month and 3 month follow up compared to baseline by the handling physician. Rating: 1) Exceptional improvement patient; 2) Very improved patient; 3) Improved patient; 4)Unaltered patient; 5) Worsened patient	Up to 12 months
Secondary	Evaluation of the pain and discomfort	Evaluation of the pain and discomfort of the treatment as reported by the subject on a visual analog scale (VAS). Scoring will consist of making a mark on a 10-point scale. Each line will be awarded a score of 0-10 according to the level of pain when 0 is no pain and 10 is maximum pain possible.	Up to 12 months
Secondary	Subject Subjective Downtime Assessment	Evaluation of the period of time following the procedure during which the subject felt unable/unwilling to go out in public.	Up to 12 months
Secondary	Patients' Reported Outcomes	Subject Satisfaction Questionnaire and GAIS- Global Aesthetic Improvement Scale Assessment. Rating: 1) Exceptional improvement patient; 2) Very improved patient; 3) Improved patient; 4) Unaltered patient; 5) Worsened patient	Up to 12 months

External Links

•   Causes of wrinkles and wrinkle prevention